Immunic Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Immunic Inc.
- Former names
- Vital Therapies Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- New York
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- IMUX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001280776
- EIN
- 56-2358443
Board of directors
-
Barclay A. Phillips · DirectorSince 2023
-
Daniel Vitt · Director · CEO and DirectorSince 2023
-
Duane Nash · Director · Executive ChairmanSince 2023
-
Elena Ridloff · DirectorSince 2026
-
Joerg Neermann · DirectorSince 2023
-
Jon Congleton · DirectorSince 2026
-
Mark N. Lampert · DirectorSince 2026
-
Michael W. Bonney · DirectorSince 2026
-
Monika Maria Toernsen · DirectorSince 2023
-
Richard Alan Rudick · DirectorSince 2023
-
Robert Thorvald Nagel · DirectorSince 2026
-
Simona Skerjanec · DirectorSince 2024
-
Tamar D. Howson · DirectorSince 2023
Chief executives
Daniel Vitt
· CEO and Director
Dates unknown
Director election results
Annual meeting of June 29, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
98.4%
-
98.5%
Board connections
6 of this board's directors also sit on 10 other boards.
- via Elena Ridloff and Mark N. Lampert
- via Michael W. Bonney
- via Simona Skerjanec
- via Michael W. Bonney
- via Jon Congleton
- via Tamar D. Howson
- via Tamar D. Howson
- via Jon Congleton
- via Mark N. Lampert
- via Mark N. Lampert
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 13, 2025 | Duane Nash Director, Officer (Executive Chairman) | Open-market purchase | +20,000 | $0.83 | $16,600 |
| Jun 5, 2025 | Tardio Jason Officer (President and COO) | Open-market purchase | +12,512 | $0.79 | $9,884 |
| Jun 5, 2025 | Joerg Neermann Director | Open-market purchase | +30,000 | $0.76 | $22,800 |
| Jun 4, 2025 | Daniel Vitt Director, Officer (CEO and Director) | Open-market purchase | +15,000 | $0.77 | $11,550 |
| Jun 4, 2025 | Joerg Neermann Director | Open-market purchase | +70,000 | $0.77 | $53,900 |
| Jun 3, 2025 | Richard Alan Rudick Director | Open-market purchase | +143,075 | $0.70 | $100,153 |
| Jun 3, 2025 | Whaley Glenn Officer (Chief Financial Officer) | Open-market purchase | +45,000 | $0.71 | $31,950 |
| May 30, 2025 | Whaley Glenn Officer (Chief Financial Officer) | Grant or award | +25,000 | $0.56 | $14,000 |
| Nov 12, 2024 | Richard Alan Rudick Director | Open-market purchase | +87,300 | $1.15 | $100,395 |
| Feb 26, 2024 | Daniel Vitt Director, Officer (President and CEO) | Open-market purchase | +14,000 | $1.31 | $18,340 |
| May 15, 2023 | Whaley Glenn Officer (Chief Financial Officer) | Open-market purchase | +5,000 | $1.75 | $8,750 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.